Partnership Coincides with the Grand Opening of Cryoport's State-Of-The-Art IntegriCell™ Houston FacilityNASHVILLE, Tenn. and HOUSTON, Oct. 22, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and Gulf Coast Regional Blood Center ("GCRBC"), a non-profit community blood center serving more than 26 counties throughout the state of Texas, today announced a strategic alliance to enhance the availability of high-quality, ma ...

Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted Solutions for Secure IVF Specimen Management and Transport NASHVILLE, Tenn. and NEW YORK, Oct. 21, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and TMRW Life Sciences ("TMRW"), a fertility technology company offering the highest standard of care in offsite storage for frozen eggs, embryos and sperm in the U.S. with th ...

Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene Therapies and mRNA-Based Treatments NASHVILLE, Tenn. and CONROE, Texas, Oct. 15, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and VGXI, Inc., (VXGI) a subsidiary of GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) today announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies ...

The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies NASHVILLE, Tenn., Oct. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of its IntegriCell™ cryopreservation services solution provided by Cryoport Systems with the opening of its new facility located at Cryoport's integrated supply chain campus in Houston, Texas. This new state-of ...

NASHVILLE, Tenn. and RANCHO CORDOVA, Calif., Sept. 25, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and SK pharmteco, a global contract development and manufacturing organization, today announced a strategic collaboration to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies. Cryoport, with its ability to provide end-to-end cell and gene therapy support servi ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, I ...

Cryoport, Inc. (NASDAQ:CYRX) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations-KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Mark Sawicki - Chief Scientific Officer Robert Stefanovich - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc David Larsen - BTIG Philip Song - Leerink Partners Matt Stanton - Jefferies Yuan Zhi - B. Riley David Saxon - Needham Operator [Abrupt Start] Cryoport Second Quart ...

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.42 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 10.81%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced a loss of $0.43, delivering a surprise of -16.22%. Over the last four quarters, the company has surpass ...

Exhibit 99.1 Cryoport Reports Second Quarter 2024 Financial Results § Revenue improved sequentially across all businesses § Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially § A record total of 684 global clinical trials supported as of June 30, 2024 § Cost reduction initiatives anticipated to result in approximately $22 million of annualized cost savings and drive Cryoport towards its goal of profitable growth, as well as a return to positive Adjusted EBITDA in 2025 § ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------|----------|--------------------|--------|----------|-------|---------------------------|------------------|----------| | | | | | | | | | | | | June 30, | Three Months Ended | | | | Six Months Ended June 30, | | | | (in thousands) | 2024 | | 2023 | % Change | 2024 | | 2023 | % Change | | Life Sciences Services | | $ 38,040$ 35,204 | | 8 % | | | $ 74,826$ 71,040 | 5 % | | BioLogistics Solutions | 34,517 | | 32,003 | 8 % | | 67,7 ...